ReNeuron’s clinical data presentation at last month’s American Academy of Ophthalmology (AAO) meeting was met with some stock price weakness. The first 8 out of a total of 22 patients in the Phase I/IIa study included a 180-day update on the three patients initially reported in February where startling vision gains were reported. The first 12 patients in the Phase I study portion will now be followed for safety only. Two recently-dosed patients experienced some procedure-related vision loss. The results to date remain encouraging, while reminding us how early on the learning curve this technology is.
19 Nov 2019
Now the dust has settled


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Now the dust has settled
ReNeuron Group plc (RENE:LON) | 113 -5.1 (-3.8%) | Mkt Cap: 64.2m
- Published:
19 Nov 2019 -
Author:
Andy Smith -
Pages:
2 -
ReNeuron’s clinical data presentation at last month’s American Academy of Ophthalmology (AAO) meeting was met with some stock price weakness. The first 8 out of a total of 22 patients in the Phase I/IIa study included a 180-day update on the three patients initially reported in February where startling vision gains were reported. The first 12 patients in the Phase I study portion will now be followed for safety only. Two recently-dosed patients experienced some procedure-related vision loss. The results to date remain encouraging, while reminding us how early on the learning curve this technology is.